Share Price | Aerovate Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Aerovate Therapeutics, Inc.?

Market Cap: As of Jun 18, Aerovate Therapeutics, Inc. has a market capitalization of 7.64 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters ending in March 2025, December 2024, September 2024, and June 2024, Aerovate Therapeutics reported net sales of 0.00 million and a net profit of -48.96 million.Balance Sheet Snapshot: As of December 2024, the company's shareholder's funds were 76.43 million, and total assets amounted to 80.33 million.

Q: What does Aerovate Therapeutics, Inc. do?

Overview: Aerovate Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -3 Million (Quarterly Results - Mar 2025) Market Cap: USD 7.64 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.01 Return on Equity: -65.24% Price to Book: 0.10Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Aerovate Therapeutics, Inc. technically bullish or bearish?

As of 4 September 2025, the technical trend for Aerovate Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including a bearish daily moving average, bearish readings in both the weekly and monthly OBV, and a bearish monthly Bollinger Band. Although the MACD shows mildly bullish signals on both weekly and monthly time frames, the overall trend remains negative. The stock has significantly underperformed the S&P 500, with a year-to-date return of -91.69% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

378.85 k

Shareholding (Dec 2025)

FII

10.14%

Held by 33 FIIs

DII

42.55%

Held by 31 DIIs

Promoter

21.77%

How big is Aerovate Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Aerovate Therapeutics, Inc. has a market capitalization of 7.64 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -48.96 million for the latest four quarters.

View full answer

What does Aerovate Therapeutics, Inc. do?

22-Jun-2025

Aerovate Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $3 million and a market cap of $7.64 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -65.24%.

View full answer

Is Aerovate Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 4, 2025, Aerovate Therapeutics, Inc. is in a bearish trend, indicated by negative moving averages and underperformance against the S&P 500, despite some mildly bullish MACD signals.

View full answer

Compare Aerovate Therapeutics, Inc. with Similar Stocks

Nautilus Biotechnology, Inc.iTeos Therapeutics, Inc.Mineralys Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 703 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.11

Return on Equity

-32.94%

Price to Book

3.92

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-32 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-15.05%

6 Months

82.52%

1 Year

-84.25%

2 Years

-98.46%

3 Years

-35.9%

4 Years

-97.52%

5 Years

0.0%

Aerovate Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-211.17%

EBIT to Interest (avg)

-67.20

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.01

Sales to Capital Employed (avg)

Tax Ratio

0.11%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.92

EV to EBIT

-7.76

EV to EBITDA

-7.76

EV to Capital Employed

-25.76

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-32.94%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

No Trend

OBV

No Trend

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 26 Schemes (25.53%)

Foreign Institutions

Held by 33 Foreign Institutions (10.14%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -490.74% vs 73.53% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-35.00",
          "val2": "-6.40",
          "chgp": "-446.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-31.90",
          "val2": "-5.40",
          "chgp": "-490.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -83.05% vs 7.81% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-113.50",
          "val2": "-74.30",
          "chgp": "-52.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-21.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-127.40",
          "val2": "-69.60",
          "chgp": "-83.05%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-35.00

-6.40

-446.88%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-31.90

-5.40

-490.74%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -490.74% vs 73.53% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-113.50

-74.30

-52.76%

Interest

0.00

Exceptional Items

-21.60

0.00

Consolidate Net Profit

-127.40

-69.60

-83.05%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -83.05% vs 7.81% in Dec 2024

All Annual Results

Company CV

About Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available